中国临床药理学杂志2018，Vol.34Issue(19)：2262-2265,4.DOI:10.13699/j.cnki.1001-6821.2018.19.006
培美曲塞注射剂联合卡铂注射液治疗表皮生长因子受体-酪氨酸激酶抑制药耐药后晚期肺腺癌患者的临床研究
Clinical trial of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor resistance
摘要
Abstract
Objective To observe the clinical efficacy and safety of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with epidermal growth factor receptor -tyrosine kinase inhibitor ( EGFR-TKI) resistance.Methods Eighty-four patients of advanced lung adenocarcinoma after EGFR -TKI resis-tance were divided into control and treatment groups with 42 cases per group.Control group received 500 mg· m-2pemetrexed per time, intra-venous drip, day 1.Treatment group was given 300 mg· m-2carboplatin per time, intravenous drip, day 1, on the basis of control group.Two groups were treated for more than 2 cycles with 21 days per cycle.The clinical efficacy, serum levels of carcino embryonic antigen ( CEA ), neuron-specific enolase (NSE) and cytokeratin antigen 19 (CYFRA21-1), and adverse drug reactions were com-pared between two groups.Results After treatment, total effective rates of treatment and control groups were 52.38%(22 cases /42 cases) and 42.86%(18 cases /42 cases) without significant difference (P>0.05).After treatment, the main indexes of treatment and control groups were compared : CEA were (37.53 ±6.28 ) and (39.15 ±5.80 ) ng· mL-1, NSE were (22.12 ±2.62 ) and (21.61 ±4.00 ) ng· mL-1, CYFRA21 -1 were ( 6.31 ±0.97 ) and (5.66 ±1.00)ng· mL-1, the differences were not statistically significant (all P>0.05).The adverse drug reactions of two groups were nausea , vomiting, myelosuppression , liver function damage , rash and fever.The total incidences of adverse drug reactions in treatment and control groups were 69.05%and 64.29% without significant difference (P>0.05).Conclusion The clinical efficacy and safety of pemetrexed injection combined with carboplatin injection in the treatment of advanced lung adenocarcinoma with EGFR -TKI resistance were equal to pemetrexed injection alone, and both could significantly inhibit the expressions of CEA , NSE and CYFRA21-1.关键词
培美曲塞注射剂/卡铂注射液/表皮生长因子受体-酪氨酸激酶抑制药/晚期肺腺癌/安全性Key words
pemetrexed injection/carboplatin injection/epidermal growth factor receptor -tyrosine kinase inhibitor/advanced lung adenocarcinoma/safety分类
医药卫生引用本文复制引用
张伟萍,应海峰,尤匡掌,贺茹依..培美曲塞注射剂联合卡铂注射液治疗表皮生长因子受体-酪氨酸激酶抑制药耐药后晚期肺腺癌患者的临床研究[J].中国临床药理学杂志,2018,34(19):2262-2265,4.基金项目
浙江省医药卫生科技计划基金资助项目(2014KYB310) （2014KYB310）
